Limited physical availability of various forms of insulin, and its concomitant high price, is a global health concern, particularly in low- and middle-income countries (LMICs) that have experienced an unprecedented increase in the prevalence of diabetes over the past two decades (1, 2). Global insulin need is expected to increase by 20% over the next decade, making insulin supply, delivery, and availability a public health imperative (3). But limited insulin production has led to a reliance on the few exporting countries that house corporate and manufacturing facilities of major multinational corporations (MNCs) (4). We use an innovative linkage of two datasets in an attempt to answer two questions: From where do countries with no domestic production source their insulin? And of these countries, are their present levels of insulin imports sufficient to treat the in-country number of persons with diabetes?

各种形式胰岛素的物理可用性有限，以及随之而来的高价，是一个全球性的健康问题，特别是在过去二十年糖尿病患病率空前增加的低收入和中等收入国家（LMIC）。1，2）。预计未来十年全球胰岛素需求将增加 20%，这使得胰岛素的供应、交付和可用性成为公共卫生的当务之急 ( 3 )。但有限的胰岛素生产导致依赖少数几个拥有大型跨国公司 (MNC) 公司和制造设施的出口国 ( 4)）。我们使用两个数据集的创新链接试图回答两个问题：没有国内生产的国家从哪里获得胰岛素？在这些国家中，它们目前的胰岛素进口水平是否足以治疗国内糖尿病患者的数量？